LYTIR

Company · RYTM

Rhythm Pharmaceuticals, Inc.

Name as listed on its exchange; filed with the SEC as RHYTHM PHARMACEUTICALS, INC.

Nasdaq's symbol directory lists RYTM on Nasdaq as “Rhythm Pharmaceuticals, Inc. - Common Stock”.

In the 12 months to Nov 8, 2026: insiders sold on 7 occasions ($32.5M); 1 planned-sale notice; 1 filing by holders of 5% or more; 1 company report (Form 8-K, since May 26, 2026).

All insider filings at the SEC · Appeared in No. 42, No. 38

Insider purchases and sales, by month (last 12 months)Insider purchases: $0 in total; Insider sales: $32.5M in total.Jun: Insider sales $3.7MAug: Insider sales $23.7MSep: Insider sales $5.1MDecJanFebMarAprMayJunJulAugSepOctNov
Insider purchases above the line: $0Insider sales below: $32.5M
Dollar value of open-market purchases and sales reported on SEC Form 4, by the month traded. Sales include pre-arranged 10b5-1 plan sales.

Insider trades · SEC Form 4

Those inside the hall

Open-market purchases and sales only. Legs one person filed for one day are combined.

Who traded

  1. Jennifer Kayden Lee, EVP, Head of North America sold on 1 day all under a 10b5-1 plan latest Aug 13, 2026 sold $8.9M
  2. Yann Mazabraud, EVP, Head of International sold on 1 day all under a 10b5-1 plan latest Aug 12, 2026 sold $6.6M
  3. Smith Hunter C, Chief Financial Officer sold on 1 day all under a 10b5-1 plan latest Aug 31, 2026 sold $6.6M
  4. David P. Meeker, President and CEO sold on 1 day all under a 10b5-1 plan latest Sep 14, 2026 sold $5.1M
  5. Lynn A. Tetrault sold on 1 day all under a 10b5-1 plan latest Jun 22, 2026 sold $3.7M
  6. Garfield Alastair, Chief Scientific Officer sold on 1 day all under a 10b5-1 plan latest Aug 13, 2026 sold $913K
  7. Shulman Joseph, Chief Technical Officer sold on 1 day all under a 10b5-1 plan latest Aug 13, 2026 sold $608K
Every trade (7)
  1. SELLDavid P. Meeker, President and CEO sold Sep 14, 2026 50,000 shares 5 legs combined 10b5-1 plan (scheduled) filing $5.1M
  2. SELLSmith Hunter C, Chief Financial Officer sold Aug 31, 2026 62,774 shares 3 legs combined 10b5-1 plan (scheduled) filing $6.6M
  3. SELLJennifer Kayden Lee, EVP, Head of North America sold Aug 13, 2026 75,834 shares 10b5-1 plan (scheduled) filing $8.9M
  4. SELLGarfield Alastair, Chief Scientific Officer sold Aug 13, 2026 7,763 shares 4 legs combined 10b5-1 plan (scheduled) filing $913K
  5. SELLShulman Joseph, Chief Technical Officer sold Aug 13, 2026 5,079 shares 10b5-1 plan (scheduled) filing $608K
  6. SELLYann Mazabraud, EVP, Head of International sold Aug 12, 2026 57,000 shares 6 legs combined 10b5-1 plan (scheduled) filing $6.6M
  7. SELLLynn A. Tetrault sold Jun 22, 2026 37,000 shares 10b5-1 plan (scheduled) filing $3.7M

Planned sales · SEC Form 144

Notice given

A Form 144 is filed before an insider sells restricted stock. It states an intent; the sale, if it happens, appears later on a Form 4. Every recent notice

  1. David Meeker filed Sep 14, 2026 Director 50,000 shares planned sale date 09/14/2026 filing $5.2M

Large holders · SEC Schedules 13D and 13G

Five percent and over

Anyone who comes to hold more than 5% of a company's voting shares must tell the SEC. A Schedule 13D is filed by a holder who may seek to influence the company; a 13G by one who states it is a passive investor. An amendment updates an earlier filing, and a stake reported as 0% means the holder says it has sold all, or nearly all, of its shares. Every recent 13D and 13G

  1. JPMORGAN CHASE & CO. filed Oct 13, 2026 Schedule 13G passive 3,563,667 shares filing 5.1%

Company reports · SEC Form 8-K

In its own words

Current reports the company filed with the SEC; most items are due within four business days of the event. Each line lists the report's items by the SEC's own titles; the filing says what happened. Reports collected since May 26, 2026; every 8-K at the SEC.

  1. Results of operations and financial condition filing Nov 3, 2026

Sources: SEC EDGAR (Forms 4, 144 and 8-K) and STOCK Act periodic transaction reports. Filings can be late, amended or wrong at the source; see methodology.